---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-292589"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2021-10-06T23:59:59+00:00"
generated_at: "2026-06-28T22:41:49.003024+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Gemini Therapeutics restructures, cuts 20% of workforce, focuses on GEM103 pivotal trial for GA

## Summary
- Workforce cut by 20% (11 positions); pre-tax restructuring charge of $1.3M–$1.6M in Q4 2021.
- CMO Samuel Barone retains title but no longer oversees regulatory/medical; Avner Ingerman promoted to CDO; Barone eligible for $100K bonus and retention pay.
- Chief Scientific Officer (Walter Strapps) and Chief People Officer (Precillia Redmond) roles eliminated by year-end 2021.
- Company shifts to development-stage, ceasing research programs to focus on GEM103 pivotal trial in GA planned for early 2022.
- CFO Brian Piekos adds Chief Business Officer role; Chair Georges Gemayel becomes Executive Chair.

## SEC filing metadata
- accession: 0001193125-21-292589
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2021-10-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.05, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000119312521292589/0001193125-21-292589-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000119312521292589/d213931d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-292589
- JSON: https://secwatch.observer/filing/0001193125-21-292589.json
- Plain text: https://secwatch.observer/filing/0001193125-21-292589.txt

## Key facts
- Executive change
  Georges Gemayel changed role as Executive Chair at Disc Medicine, Inc..
  - Action: transitioned to serve as
  - Role: Executive Chair
  source text: Finally, Georges Gemayel, Ph.D., will transition to serve as the Executive Chair of the Company’s Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816736/000119312521292589/0001193125-21-292589-index.htm
- Executive change
  Samuel Barone changed role as Chief Medical Officer at Disc Medicine, Inc..
  - Action: modified role
  - Role: Chief Medical Officer
  source text: On October 4, 2021, the Company’s Chief Medical Officer, Samuel Barone, M.D., entered into an agreement with the Company (the “Retention Agreement”) to modify his role and responsibilities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816736/000119312521292589/0001193125-21-292589-index.htm
- Executive change
  Brian Piekos was appointed as Chief Business Officer at Disc Medicine, Inc..
  - Action: appointed
  - Role: Chief Business Officer
  source text: In addition, effective as of October 4, 2021, the Company has appointed Brian Piekos, the Company’s Chief Financial Officer, the additional title of Chief Business Officer, and Mr. Piekos has assumed additional leadership responsibilities for various functions including manufacturing, business development and investor relations.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816736/000119312521292589/0001193125-21-292589-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.